Informazioni generali
  • Categoria della malattia Malattie nutrizionali e metaboliche (BASEC)
  • Fase dello studio N/A (ICTRP)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Aarau
    (BASEC)
  • Responsabile dello studio Prof. Dr. med. Philipp Schütz, MPH philipp.schuetz@ksa.ch (BASEC)
  • Fonte dati BASEC: Importato da 16.02.2026 ICTRP: Importato da 01.03.2025
  • Ultimo aggiornamento 16.02.2026 08:56
HumRes66383 | SNCTP000006279 | BASEC2024-02519 | NCT06826105

Effect of a low-dose enzyme together with a dietary supplement on nutrient absorption in patients at risk of malnutrition.

  • Categoria della malattia Malattie nutrizionali e metaboliche (BASEC)
  • Fase dello studio N/A (ICTRP)
  • Stato di reclutamento reclutamento in corso (BASEC/ICTRP)
  • Luogo dello studio
    Aarau
    (BASEC)
  • Responsabile dello studio Prof. Dr. med. Philipp Schütz, MPH philipp.schuetz@ksa.ch (BASEC)
  • Fonte dati BASEC: Importato da 16.02.2026 ICTRP: Importato da 01.03.2025
  • Ultimo aggiornamento 16.02.2026 08:56

Descrizione riassuntiva dello studio

In cases of malnutrition, dietary supplements are given as standard treatment. Since these do not always work optimally or are not well tolerated, we want to test in this study whether digestive pancreatic enzymes can help improve the absorption of dietary supplements and make them better tolerated.

(BASEC)

Intervento studiato

Malnutrition

(BASEC)

Malattie studiate

Malnutrition risk

(BASEC)

Criteri di partecipazione
  • Hospitalized at the site Nutritional Risk Screening 2002 (NRS-2002) ≥ 3
  • eGFR ≥ 30 mL/min/1.73 m2 (EPI-CKD) based on history (not older than 6 months)

(BASEC)


Criteri di esclusione
  • Patients with terminal illness, acute cardiovascular event (<2 days) diagnosed exocrine pancreatic insufficiency (EPI), treated with pancreatic enzyme replacement therapy (PERT)
  • Patients for whom transplantation or newly initiated dialysis is planned within the next 6 months.
  • Patients for whom colectomy, small bowel resection, or cholecystectomy is planned

(BASEC)

Luogo dello studio

Aarau

(BASEC)

Switzerland (ICTRP)

Sponsor

Kantonsspital Aarau

(BASEC)

Contatto per ulteriori informazioni sullo studio

Persona di contatto in Svizzera

Prof. Dr. med. Philipp Schütz, MPH

+41628386880

philipp.schuetz@ksa.ch

Kantonsspital Aarau

(BASEC)

Informazioni generali

Kantonsspital Aarau

+41 62 838 68 80+41 62 838 68 80

philipp.schuetz@ksa.chphilipp.schuetz@ksa.ch

(ICTRP)

Nome del comitato etico approvante (per studi multicentrici solo il comitato principale)

Commissione d'etica svizzera nord-ovest/centrale EKNZ

(BASEC)

Data di approvazione del comitato etico

18.02.2025

(BASEC)


ID di studio ICTRP
NCT06826105 (ICTRP)

Titolo ufficiale (approvato dal comitato etico)
Effect of low dose pancrelipase with an oral nutritional supplement to improve nutrient bioavailability in patients at increased risk of malnutrition (BASEC)

Titolo accademico
Effect of Low Dose Pancrelipase With an Oral Nutritional Supplement to Improve Nutrient Bioavailability in Patients at Increased Risk of Malnutrition (ICTRP)

Titolo pubblico
Pancrelipase With Nutritional Supplement in Patients at Risk of Malnutrition (EFFORT-ENZO) (ICTRP)

Malattie studiate

Malnutrition

(ICTRP)



Intervento studiato

Drug: ZenpepDrug: Placebo

(ICTRP)



Tipo di studio
Interventional (ICTRP)

Disegno dello studio

Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

(ICTRP)



Criteri di inclusione/esclusione

Inclusion Criteria:

  • Informed Consent as documented by signature
  • Male or female 70 years of age or older
  • Hospitalized at site
  • Nutrition Risk Screening 2002 (NRS-2002) = 3
  • eGFR = 30 mL/min/1.73 m2 (EPI-CKD) based on medical history (no older than 6 months)
  • Ability to eat orally

Exclusion Criteria:

  • Patients with acute cardiovascular event = 2 days
  • Patients with terminal conditions
  • Patients diagnosed with pancreatic exocrine insufficiency (EPI) treated with pancreatic enzyme replacement therapy (PERT)
  • Patients having a planned transplant or new-onset dialysis in the next 6 months.
  • Patients having a colectomy, resection of the small intestine or cholecystectomy
  • Known hypersensitivity to any of the substances or excipients of the ONS or the medicinal product

(ICTRP)



non disponibile

Endpoint primari e secondari

Incremental area under the curve of total branched-chained amino acid concentration

(ICTRP)



Incremental area under the curve of essential amino acids (EAAs);Incremental area under the curve of total amino acids;Incremental area under the curve of free fatty acids;Incremental area under the curve of triglycerides;Water load satiety test (WLST);Exploratory subgroup analysis;Incremental area under the curve of glucose

(ICTRP)



Data di registrazione
non disponibile

Inclusione del primo partecipante
non disponibile

Sponsor secondari
non disponibile

Contatti aggiuntivi
Philipp Schuetz, Prof. MDPhilipp Schuetz, Prof. MDPhilipp Schuetz, Prof. MD, philipp.schuetz@ksa.chphilipp.schuetz@ksa.ch, +41 62 838 68 80+41 62 838 68 80, Kantonsspital Aarau (ICTRP)

ID secondari
2024-02519, ka24Schuetz (ICTRP)

Risultati-Dati individuali dei partecipanti
non disponibile

Ulteriori informazioni sullo studio
https://clinicaltrials.gov/ct2/show/NCT06826105 (ICTRP)

Risultati dello studio

Riepilogo dei risultati

non disponibile

Link ai risultati nel registro primario

non disponibile